Related Experiment Video
Updated: Jul 14, 2026
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
Published on: July 5, 2021
Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas
Francesca Orzan1, Maria Rosa Terreni, Mauro Longoni
1Department of Biology and Genetics, Medical Faculty, University of Milan, 20133 Milano, Italy.
Abstract:
Chordomas are rare neoplasms arising along the axial skeleton. Up to now, the most suitable therapeutic approach is based on a combination of surgical excision and radiotherapy. Chemotherapy in not applied due to its reported low efficacy. Recently, evidence on the efficacy of Imatinib mesylate in two patients has been reported. We analyzed 14 chordoma samples for the expression of the Imatinib mesylate targets by means of RT-PCR and immunohistochemistry and found that PDGFR alpha and PDGFR beta are in some cases expressed in neoplastic cells, while the stromal counterpart of the same tumor shows the above receptors. Findings on the PDGFA/PDGFB expression suggest a receptor-activated status. Our study provides new insights into the specific localization of Imatinib mesylate targets in skull base chordomas that could be taken into account for the setting up of a pharmacological treatment for this tumor.
Insights
This study investigated Imatinib mesylate targets in chordoma tumors. Researchers found that platelet-derived growth factor receptors (PDGFR) alpha and beta are present in tumor cells and surrounding stroma, suggesting potential therapeutic applications.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chordomas are rare axial skeleton neoplasms typically treated with surgery and radiotherapy.
- Chemotherapy has shown limited efficacy for chordomas.
- Recent case reports suggest potential efficacy of Imatinib mesylate for chordoma treatment.
Purpose of the Study:
- To analyze the expression of Imatinib mesylate targets in chordoma samples.
- To investigate the specific localization of these targets within tumor cells and the tumor microenvironment.
- To provide insights for developing targeted pharmacological treatments for chordomas.
Main Methods:
- Analysis of 14 chordoma samples.
- Utilized reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry.
- Assessed the expression of platelet-derived growth factor receptor (PDGFR) alpha and beta.
Main Results:
- PDGFR alpha and PDGFR beta were found to be expressed in neoplastic cells in some cases.
- The stromal component of the tumors also showed expression of these receptors.
- Expression patterns of PDGFA/PDGFB suggest a receptor-activated status.
Conclusions:
- This study identifies specific localization of Imatinib mesylate targets in skull base chordomas.
- The findings suggest that PDGFRs are potential targets for pharmacological intervention in chordoma.
- Further research into Imatinib mesylate and similar targeted therapies is warranted for chordoma treatment.
More Related Videos
09:24Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
Published on: June 9, 2016
11:09Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Published on: July 13, 2010